4.8 Article

A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease

期刊

NATURE MEDICINE
卷 21, 期 3, 页码 276-+

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3776

关键词

-

资金

  1. German Research Foundation [SFB1035]
  2. Bayerisches Staatsministerium fur Wirtschaft, Infrastruktur, Verkehr und Technologie (m4 Award)
  3. Federal Ministry of Education and Research (BMBF
  4. PersoMed)
  5. European Commission [FP7-PEOPLE-20112011-IIF 301193, Hsp90NMR]
  6. European Molecular Biology Organization [EMBO ALTF 1255-2011]

向作者/读者索取更多资源

One function of the glucocorticoid receptor (GR) in corticotroph cells is to suppress the transcription of the gene encoding proopiomelanocortin (POMC), the precursor of the stress hormone adrenocorticotropin (ACTH)(1). Cushing disease is a neuroendocrine condition caused by partially glucocorticoid-resistant corticotroph adenomas that excessively secrete ACTH, which leads to hypercortisolism(2-4). Mutations that impair GR function explain glucocorticoid resistance only in sporadic cases(5,6). However, the proper folding of GR depends on direct interactions with the chaperone heat shock protein 90 (HSP90, refs. 7,8). We show here that corticotroph adenomas overexpress HSP90 compared to the normal pituitary. N- and C-terminal HSP90 inhibitors act at different steps of the HSP90 catalytic cycle to regulate corticotroph cell proliferation and GR transcriptional activity. C-terminal inhibitors cause the release of mature GR from HSP90, which promotes its exit from the chaperone cycle and potentiates its transcriptional activity in a corticotroph cell line and in primary cultures of human corticotroph adenomas. In an allograft mouse model, the C-terminal HSP90 inhibitor silibinin showed anti-tumorigenic effects, partially reverted hormonal alterations, and alleviated symptoms of Cushing disease. These results suggest that the pathogenesis of Cushing disease caused by overexpression of heat shock proteins and consequently misregulated GR sensitivity may be overcome pharmacologically with an appropriate HSP90 inhibitor.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据